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Abstract
Metergoline, a serotonin receptor antagonist, was labeled with carbon-11 in order to evaluate
pharmacokinetics and distribution in non-human primates using positron emission tomography.
[11C]Metergoline had moderate brain uptake and exhibited heterogeneous specific binding which
was blocked by pretreatment with metergoline and altanserin throughout the cortex. Nonspecific
binding and insensitivity to changes in synaptic serotonin using citalopram limit its potential as a
PET radiotracer. However, the characterization of [11C]metergoline pharmacokinetics and binding
in the brain and peripheral organs using PET improves our understanding of metergoline drug
pharmacology.
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1. Introduction
Metergoline is a relatively old ergot-derived drug that has been explored in a variety of medical
applications,1 including seasonal depression2 and prolactin hormone regulation.3 It has also
been used in veterinary medicine as a pregnancy termination drug for dogs.4 The
pharmacological effects of metergoline have been primarily attributed to its interactions with
the serotonin (5-hydroxytryptamine, (5HT)) system. Metergoline acts as an antagonist at many
of the 5HT receptor subtypes (with binding affinities reported as low as 120 pM) and has also
been shown to interact with certain dopamine receptors albeit with lower potency.5 Since
initially reported in 1965,6 metergoline has been used in hundreds of behavioral pharmacology
experiments as a probe for 5HT receptor function.7
We were initially attracted to metergoline during the development of a new method to label
compounds with carbon-11, a positron-emitting isotope with a 20.4 min half life.8 During the
course of these studies, which were aimed at direct fixation of 11CO2 in carbamates, we were
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table to synthesize [11C]metergoline with high efficiency and relative ease. Because of the
interesting pharmacology associated with the use of metergoline as a serotonergic drug, we
decided to characterize [11C]metergoline binding in the non-human primate brain using
positron emission tomography (PET). This was in part prompted by an earlier in vitro
characterization of tritium labeled metergoline.9
Nearly three decades ago, [3H]metergoline was explored as a ligand for serotonin receptor
autoradiography and showed specific binding for serotonin receptors 10–400 times more
sensitive to serotonin- than dopamine- receptor antagonists, depending on the brain region and
blocking drug used. Although [3H]metergoline displayed suitable characteristics as a
radioligand for 5HT receptors, it was never subsequently used for this purpose (perhaps due
to the development of more sub-type specific radioligands).
While several serotonin ligands have been developed as PET radiotracers for various receptor
subtypes (see Figure 1 for examples), there remain limitations in the ability to probe the
serotonin system using PET, primary among them being radiotracer sensitivity to synaptic
serotonin concentration. 10 In order to determine the potential of [11C]metergoline as a
serotonin radiotracer and to characterize its binding in vivo, we examined its baseline
pharmacokinetics and distribution in both the brain and peripheral organs as well changes in
binding after pretreatment with unlabeled metergoline, altanserin, and citalopram.
2. Results and Discussion
2.1 Chemistry
Synthesis of a labeling precursor was accomplished by hydrogenolysis of metergoline, Scheme
1. The resulting amine (2) was isolated in nearly quantitative yield without chromatographic
separation. Less than 0.1% of the starting material remained, an important consideration for
PET imaging given that contaminating starting material would have a direct impact on
radiotracer specific activity. The facile “deprotection” of metergoline highlights one key
advantage of using a carbon-11 carbamate labeling approach when compared to, for example,
demethylation to form a labeling precursor.
Carbon-11 labeling was carried out using DBU-mediated direct fixation of 11CO2. In one pot,
a solution the amine precursor (2), benzyl chloride, and DBU in DMF were combined and
treated with high specific activity 11CO2. The sealed vessel was heated for 5–6 min.
Unreacted 11CO2 was removed by acidification of the reaction solution followed sparging with
helium. Purification of [11C]metergoline (3) was accomplished using reversed phase HPLC.
Of the radioactivity loaded on the column, >75% was [11C]metergoline with almost the entire
balance being incorporated into a single, slightly more polar compound. Byproduct formation
and yield was batch dependant and we are interested in determining the structure of this side
product in order to learn about other direct reaction modes for 11CO2 under these conditions,
but to date have not been able to isolate the byproduct in sufficient quantities for
characterization.
After purification and formulation, the radiochemical yield of [11C]metergoline was ~35% and
the specific activity was consistently >3 Ci/μmol.
2.2 Lipophilicity and Plasma Protein Binding
Before performing in vivo PET studies, we examined the lipophilicity and plasma protein
binding of [11C]metergoline in vitro. The lipophilicity (logD, 3.30 ± 0.32, n = 6) of [11C]
metergoline was within the range of values predicted to facilitate good BBB penetration.11
However, we noted >99% of [11C]metergoline was bound to plasma proteins (0.55% unbound,
n =2), which we surmised would limit the overall uptake of the labeled compound in the brain.
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t2.3 Pharmacokinetics and Distribution (Brain)
[11C]Metergoline was introduced intravenously to anesthetized, otherwise drug naive, baboons
to determine its level of uptake and distribution in various tissues. Given its use as a tool in
pharmacological neuroscience, we were particularly interested in the binding characteristics
of [11C]metergoline in the brain, but we have also examined [11C]metergoline binding in
peripheral tissues.
[11C]Metergoline exhibited heterogeneous binding throughout the brain with the greatest
concentration observed in the cortex, particularly in the occipital cortex, Figure 2a. The average
concentration of [11C]metergoline in the brain during early time points was 0.01 %ID/cc (2–
10 min), which corresponds to ~1.5% of the total injected dose. This is roughly 1/3 of the
uptake observed for highly brain penetrate compounds, such as [11C]cocaine, which was
unexpectedly high given the high degree of plasma protein being for [11C]metergoline. The
time-activity curves for specific brain regions also exhibited heterogeneous profiles with
various rates of clearance, Figure 3a. The initial imaging data was consistent with the known
distribution of serotonin receptors in the brain and similar to other PET radiotracers, most
notably [18F]altanserin, which is currently one of the most common agents for human 5HT2a
characterization.12
2.3.1 Pharmacological Blocking Studies—To further characterize the binding of [11C]
metergoline in the brain, we performed a series of preliminary blocking studies. Pretreatment
with non-radioactive metergoline (1 mg i.v., 5 min prior to radiotracer) was used to discriminate
specific from nonspecific binding. Dose corrected images indicated that pretreatment had a
marked impact on [11C]metergoline binding, particularly in the cortex, which was also evident
from changes in the brain region time-activity curves, Figure 3b. However, ~50% of the signal
relative to baseline was observed at this dose. We attribute this primarily to the nonspecific
binding component; however it may be an overestimate. For safety, we did not examine higher
blocking doses with metergoline. Instead, we determined the effects of pretreatment with
altanserin (0.5 mg/kg i.v.) and citolopram (5.0 mg/kg i.v.).
Quantification of [11C]metergoline binding was accomplished by Logan graphical analysis
using a metabolite corrected plasma input curve. This analysis was performed for all brain
regions however only occipital cortex binding data are given for clarity. We used this method
to assess the change in binding after pretreatment with altanserin and citalopram. The
distribution volumes (VT) using this method ranged from 10–18ml/ml with moderate test-retest
variability. Using the cerebellum as a reference region, we calculated BPND which appeared
to be a more stable measurement (i.e. lower standard deviation) for both intra-subject and inter-
subject scans. Cerebellum is commonly used as reference region for 5HT receptor binding.
However, in our case the cerebellum is not an ideal reference region because we did observe
some specific binding (albeit small) in this region during the metergoline challenge
experiments. Nonetheless, this estimate was sufficient for a preliminary comparison of baseline
scans to those following a pharmacological challenge.
Baseline BPND in the occipital cortex was 0.3 and was considerably reduced by pretreatment
with metergoline and altanserin, but not with citalopram. For comparison, baseline BPND for
[18F]altanserin in the occipital cortex is approximately 3. Blockade of [11C]metergoline
binding with altanserin suggests 5HT2a binding dominates when metergoline is administered
at these low tracer concentrations. Unfortunately, the high degree of non-specific binding
clearly limits the dynamic range for BPND and the potential utility of [11C]metergoline as a
PET radiotracer.
2.3.1 PDSP Receptor Binding Analysis—We also submitted metergoline to the
Psychoactive Drug Screening Program (PDSP) for full in vitro binding characterization, Table
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t1. As expected, metergoline inhibited many of the 5HT receptor subtypes at low nanomolar
concentrations. Consistent with other reports, metergoline showed high affinity in the screen
for dopamine receptors, particularly D1 and D4, as well as muscarinic receptors. We also
observed nanomolar interactions with norepinephrine and opioid receptors.
The high affinity promiscuity of metergoline obviously limits our ability to interpret PET
imaging data for [11C]metergoline even though we noted large reductions in specific binding
with a 5HT2a selective drug pretreatment.
2.4 Pharmacokinetics and Distribution (Peripheral)
Dynamic PET imaging was also performed with the baboon torso in the field of view to examine
peripheral organ pharmacokinetics and distribution. Representative time-activity curves for
[11C]metergoline and its radioactive metabolites are given in Figure 5. Gall-bladder was
primary site of accumulation reaching 0.3–0.5%ID/cc.
Serotonin receptors are found throughout the periphery with high concentration in the gut,
smooth muscle, and on platelets. Thus, we wanted to determine if [11C]metergoline would
exhibit specific binding to peripheral 5HT receptors, which have been targets for appetite
suppression.13 We were also interested in examining heart uptake, given that several ergot (and
related) drugs targeting 5HT receptors (particularly 5HT2b) have been associated with cardiac
fibrosis and pulmonary hypertension.14 From baseline PET scans, we were intrigued by uptake
of carbon-11 in the heart wall, Figure 6. This uptake was not affected pretreatment with
unlabeled metergoline and does not likely represent a specific receptor interaction.
3. Conclusions
Metergoline can be efficiently and reproducibly labeled with carbon-11 using a DBU-mediated
direct fixation of high specific activity 11CO2. [11C]Metergoline has good brain penetration
and uptake in non-human primates, with kinetics suitable for quantitative analysis; however
blocking studies revealed that [11C]metergoline exhibits a mixture of specific and non-specific
binding which limits its usefulness as a radiotracer. [11C]Metergoline binding was not sensitive
to pre-synaptic SERT blockade and the resulting increase in synaptic serotonin with citalopram.
PET imaging studies revealed non-saturable accumulation of [11C]metergoline and/or its
metabolites in the heart. Given the past and likely continued use of metergoline, the
characterization of [11C]metergoline pharmacokinetics and binding in vivo should improve of
interpretation behavioral pharmacology experiments.
4. Methods
4.1. General
[11C]Carbon dioxide was generated from a nitrogen/oxygen (1000 ppm) target (14N(p,α)11C)
using an EBCO TR 19 cyclotron (Advanced Cyclotron Systems INC. Richmond, Canada).
High performance liquid chromatography (HPLC) purification was performed by a Knauer
HPLC system (Sonntek Inc., Woodcliff Lake, NJ, USA) with a model K-5000 pump, a
Rheodyne 7125 injector, a model 87 variable wavelength monitor, and a NaI radioactivity
detector.
Specific activity was determined by measuring the radioactivity and the mass; the latter was
derived from a standard curve (UV absorbance at 254 nm by peak area) after HPLC injection
of different quantities of the authentic reference compound. Radiochemical purity was
determined by HPLC and verified by thin-layer chromatography (TLC) using and measuring
radioactivity distribution on Macherey–Nagel polygram sil G/UV254 plastic-backed TLC
plates with a Bioscan system 200 imaging scanner (Bioscan Inc., Washington, DC). 11C-
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tRadioactivity was measured by a MINAXI γ 5000 automated gamma counter (Packard
Instrument, Meriden, CT). All measurements were decay corrected. All chemicals were
purchased from Sigma-Aldrich, with the exception of anhydrous DMF, which was obtained
from Acros Organics (USA).
4.2 Chemistry
4.2.1. Synthesis of Labeling Precursor (2)—Metergoline (300 mg, 0.74 mmol) was
dissolved in 15 ml of MeOH and 50 mg of palladium on activated charcoal (10% wt) was
added. While stirring, the mixture was sparged with a slow stream of hydrogen gas for 20
minutes. The reaction flask was sealed under an atmosphere of H2 (using a H2 filled balloon)
and stirred at room temperature. Reaction progress was monitored by TLC (MeOH as the
eluent) until no metergoline remained (typically 12–16h). At this point, the reaction mixture
was filtered through celite to remove the activated charcoal and the solvent was removed under
reduced pressure. The resulting residue was dissolved in a small volume of ethyl acetate and
concentrated under reduced pressure. This process was repeated until a white solid remained
(60 mg, 0.22 mmol, 30%), which required no additional purification. 1H NMR (400 MHz,
CDCl3), δ: 7.20 (t, J = 8 Hz, 1H), 7.12 (d, J = 8 Hz, 1H), 6.93 (d, J = 4 Hz, 1H), 6.74 (s, 1H),
3.76 (s, 3H), 3.43–3.38 (dd, J =16 Hz, 4 Hz, 1H), 3.13 (d, J = 8 Hz, 1H), 2.98 (m, 1H), 2.76–
2.66 (m, 4H), 2.49 (s, 3H), 2.18–2.12 (m, 1H), 1.96–1.91 (m, 2H), 1.15–1.06 (q, J = 12 Hz,
1H). 13C NMR (125 MHz, CDCl3), δ: 134.6, 133.8, 126.7, 122.9, 122.7, 112.8, 111.0, 106.9,
67.8, 62.0, 46.8, 43.6, 40.8, 39.6, 33.0, 32.4, 27.2.
4.2.2. Synthesis of [11C]Metergoline (3)—Labeling precursor 2 (1 mg) dissolved in 100
μL of DMF was combined with 100 μL of a solution of DBU (300 mM in DMF) and then
treated with a 100 μL aliquot of benzyl chloride (300 mM in DMF) in a cone-bottom 5 mL
reaction vessel equipped with a septum and screw cap. The resulting solution was sparged with
helium for 15 min. At the end-of-bombardment, the target gas from the cyclotron was passed
through the solution and 11CO2 was captured. The expansion of the target gas through the
reaction solution required ~2.5 min. During some syntheses,11CO2 from the target was
captured on Alltech 4Å, 50–80 mesh crushed mol. sieves (330 mg packed in a ¼” ID SS tube)
using a custom built trap and release module. The 11CO2 was released from the mol. sieves at
250–300°C in a stream of helium (~50 mL/min) and captured in the precursor/DBU solution
as detailed above. This process required 5–6 min.
After 11CO2 was captured in the reaction solution (using either method), the vessel was then
heated to 75°C for 7.5 min at which time 100 μL of trifluoroacetic acid was added. The volatile
activity was removed by sparging the solution with He. (This required ~0.5 min). The solution
was diluted with 1.0 ml of water and purified by HPLC (Luna C18(2) column (250 × 10 mm,
5 μm particles) using a two solvent (A:B) gradient elution at 5mL/min: Solvent A: 0.1M (aq)
ammonium formate, Solvent B: MeCN; 80:20 for 3 min, changing to 10:90 linearly from 3–
23 min and holding until 30 min). The fraction containing [11C]metergoline was collected
(retention time 15.5–16.5 min), and the solvent was removed on a rotary evaporator. Following
purification and concentration, [11C]metergoline was dissolved in saline (4.0 mL) and the
resulting solution was filtered through an Acrodisc 13-mm Syringe Filter with 0.2 μm HT
Tuffryn Membrane (Pall Corporation, Ann Arbor, MI) into a sterile vial for delivery to the
imaging facility. The radiochemical yield based on the loss of volatile 11CO2 and HPLC was
typically 35% (decay corrected to EOB). Specific activity for the imaging studies was 3.2–
5.1Ci/μmol (calculated at EOB). Typical radiosynthesis and purification time was 45 min.
For quality control (i.e. identity verification and radiochemical purity), analytical TLC and
HPLC were performed. [11C]Metergoline was cospotted with unlabelled (i.e. non-radioactive)
standard and analyzed by radioTLC (MeOH with 0.1% TEA, Rf = 0.5). Analytical HPLC was
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taccomplished using a Phenomenex Gemini C18 column (250 × 4.6 mm, 5 μm particles) using
an isocratic elution (1.0 ml/min, 60% aqueous mobile phase to 40% MeCN). Using this method,
[11C]metergoline eluted at 8.5 min. Radiochemical purity exceeded 99% as determined by both
radioHPLC and radioTLC and chemical purity was >95% as determined from analytical HPLC
with 254 nm detection.
4.3 LogD Determination
An aliquot (~50 μl) of the formulated [11C]metergoline was added to a test tube containing 2.5
mL of octanol and 2.5 mL of phosphate buffer solution (pH 7.4). The test tube was mixed by
vortex for 2 min and then centrifuged for 2 min to fully separate the aqueous and organic phase.
A sample taken from the octanol layer (0.1 mL) and the aqueous layer (1.0 mL) were saved
for radioactivity measurement. An additional aliquot of the octanol layer (2.0 mL) was carefully
transferred to a new test tube containing 0.5 mL of octanol and 2.5 mL of phosphate buffer
solution (pH 7.4). The previous procedure (vortex mixing, centrifugation, sampling, and
transfer to the next test tube) was repeated until six sets of aliquot samples had been prepared.
The radioactivity of each sample was measured in a well counter (Picker, Cleveland, OH). The
logD of each set of sample was derived by the following equation: logD = log (decay-corrected
radioactivity in octanol sample × 10/decay-corrected radioactivity in phosphate buffer sample).
4.4 Plasma Protein Binding Assay
An aliquot of [11C]metergoline in saline (10 μl) was added to a sample of baboon plasma (0.8-
mL, pooled from at least 4 separate animals). The mixture was gently mixed by repeated
inversion and incubated for 10 min at room temperature. Following incubation a small sample
(20 μl) was removed to determine the total radioactivity in the plasma sample (AT;
AT=Abound+Aunbound). An additional 0.2 mL of the plasma sample was placed in the upper
compartment of a Centrifree® tube (Amicon, Inc., Beverly, MA) and then centrifuged for 10
min. The upper part of the Centrifree tube was discarded and an aliquot (20 μl) from the bottom
part of the tube was removed to determine the amount of radioactivity that passed through the
membrane (Aunbound). Plasma protein binding was derived by the following equation: %
unbound=Aunbound×100/AT.
4.5 PET imaging and arterial plasma sampling
All experiments with animals were approved by the Brookhaven Institutional Animal Care and
Use Committee. Four female Papio anubis baboons were used for the 15 PET scans performed
for this study. Anesthesia was accomplished by an intramuscular injection of ketamine
hydrochloride (10 mg/kg) and then maintained with oxygen (800 mL/min), nitrous oxide (1500
mL/min) and isoflurane (Forane, 1–4%) during scanning. [11C]Metergoline was injected
through a catheter placed in a radial arm vein, and arterial blood was sampled through a catheter
in the popliteal artery at the following time intervals: every 5 s for 2 min, then 2, 5, 10, 20, 30,
45, 60 and 90 min. Heart rate, respiration rate, pO2 and body temperature were checked during
the PET scanning. Dynamic PET imaging was performed by Siemens HR+ (Siemens high-
resolution, whole-body PET scanner with 4.5×4.5×4.8 mm resolution at the center of field of
view) with the brain or torso in the field of view, for a total of 90 min with the following 55
time frames in 3D mode: 12×5, 12×10, 6×20, 6×30, 8×60, 2×120, 4×300, 5×600 s. Prior to
each emission scan, a transmission scan was obtained by rotating a 68Ge rod source to correct
for attenuation. A total of 15 studies in the baboon were conducted (3 × brain, 1 × torso kinetics,
1 × whole body following dynamic brain scan), with an average injected dose of 3.72 ± 0.90
mCi (n = 15).
Six of the studies were performed (as detailed above) following intravenous pretreatment with
one of the following drugs: metergoline (n = 2, brain; n = 1 torso), citalopram (n = 2), and
altanserin (n = 1). Metergoline (1 mg) was dissolved in a solution of 0.5 mL EtOH and 0.5 mL
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t0.1 M HCl and passed through a sterilizing filter into a multi-injection vial containing 9 mL
of sterile saline. The 1mg (10 mL) metergoline pretreatment was administered as a bolus 10
min prior to injection of [11C]metergoline. Citalopram-HBr (5.0 mg/kg based on the free base)
was dissolved in 10 mL of saline and passed through a sterilizing filter into a multi-injection
vial. The citalopram solution was administered as a bolus 20 min prior to injection of [11C]
metergoline. Altanserin (0.5 mg/kg) was dissolved in 1.5 mL of 2% HCl in EtOH, diluted to
30 mL with saline, and passed through a sterilizing filter (final pH ~5.5). Altanserin was
administered 15 min prior to injection of [11C]metergoline.
4.6 Plasma Metabolite Analysis
The percent of unmetabolized radiotracer in the sampled baboon plasma was determined using
a robot solid phase extraction (SPE) method and validated using manual HPLC analysis.15 For
the robot SPE method baboon plasma (~0.2 ml), sampled at given time points during the PET
study (typically 1, 5, 10, 30, 60 and 90 min), was added to water (3 ml) at room temperature
and mixed by vortex. The mixture was then applied onto Varian BondElut CN cartridges (500
mg, preconditioned with 5 ml methanol followed 5 ml water then preloaded with 2 ml of
deionized water). Polar metabolites were removed by two 5 ml deionized water rinses. The
percentage radioactivity remaining on the cartridge was reported as the % of unmetabolized
radiotracer. A control consisting of baboon plasma at time zero was mixed with radiotracer
and analyzed to confirm that unmetabolized radiotracer did not elute under these conditions.
For validation by HPLC, baboon plasma (0.2–0.5 ml) sampled at various time points during
the PET study was counted, added to a solution of unlabeled standard (20 μl of a 1 mg/ml
solution) in methanol (.5 ml), subjected to an ultrasonic cell disruptor and centrifuged. Both
supernatant and pellet were counted to determine the percent extracted. The supernatant was
analyzed by HPLC (Phenonenx Ultramex 5 C18 5u 250 × 5.6 mm column using 80:20 MeOH:
0.1 M ammonium formate with 0.1% triethylamine at 1.2 mL/min). The fraction of
radioactivity coeluting with the unlabeled standard, relative to the total radioactivity collected
from the HPLC column was reported as the % of unmetabolized radiotracer, Figure 7. Total
activity recovered from the HPLC column was compared to a counting standard; generally
recoveries from the column were 92–110%.
4.7 Image analysis
Emission data from the dynamic scans (PET) were corrected for attenuation and reconstructed
using filtered back projection. After ECAT7 files were converted to ANALYZE format and
time frames 5–30 were summed for each file, images were coregistered with published template
images16 (H2
15O PET and MR) manually and then normalized (12 nonlinear iterations) using
PMOD® (PMOD Technologies, Ltd). Regions of interest (ROIs) on the baboon and rodent
brain were drawn on summed images and then projected to the dynamic images to obtain time
activity curves (TACs) expressed as %injected dose/cm3 (decay corrected) versus time.
Regions of interest (ROIs) on the baboon brain were drawn on summed images and then
projected to the dynamic images to obtain time activity curves (TACs) expressed as %injected
dose/cm3 (decay corrected) versus time. A common ROI file was used to generate TACs each
study. Torso data we were analyzed using Amide Software and manually drawn 3-D ROIs.
4.8 Image analysis
Logan graphical analysis derived from the TACs and metabolite-correct plasma data was used
to determine distribution volume (VT).17 This analysis was accomplished with General Kinetic
Modeling Tool (PKIN) in PMOD. Binding potential (BPND) was calculated by taking the ratio
of a given VT to a reference region (cerebellum) and subtracting 1 (the presumed non-specific
contribution).
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Examples of 11C- and 18F-labeled 5HT imaging agents
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tFigure 2.
Representative [11C]metergoline PET images from a baseline (a) and blocking (b) study carried
out in the same baboon. Images were summed 30–90 min and dose corrected (3.04 and 3.17
mCi, respectively) after spatial co-registration.
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tFigure 3.
Representative time-activity curves (TACs) for baboon brain regions of interest: (left) averaged
[11C]metergoline baseline TACs (n = 7); (right) averaged TACs from blocking studies with
cold metergoline (n = 3).
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tFigure 4.
Assessment of [11C]metergoline binding and specificity. Data presented are from Logan
graphical analysis of occipital cortex TACs.
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tFigure 5.
Representative time-activity curves (TACs) for baboon peripheral organs. (Gall bladder
omitted).
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tFigure 6.
Preliminary assessment of [11C]metergoline uptake in the baboon heart. (a) Time-activity
curves for a region of interest placed on the heart wall during three PET scans. Pretreatment
with cold metergoline (1 mg i.v., 10 min prior to radiotracer administration) was used to assess
binding saturability. (b) Representative images showing heart uptake (PET data summed from
5–20 min, NIH color scale) overlaid on transmission data (grayscale).
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Evaluation of [11C]metergoline metabolism using plasma samples.
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aConditions: (i) H2, Pd/C, MeOH, 25°C, 12 h, 98%. (ii) 11CO2, DBU, BnCl, DMF, 75°C, 10
min 35% RCY
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